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Abstract
HIV is known to spread efficiently both in a cell-free state and from cell to cell, however the relative importance of the cell-cell
transmissionmode innaturalinfectionhasnotyet been resolved.Likewisetowhat extentcell-cell transmissionisvulnerable to
inhibition by neutralizing antibodies and entry inhibitors remains to be determined. Here we report on neutralizing antibody
activity during cell-cell transmission using specifically tailored experimental strategies which enable unambiguous
discrimination between the two transmission routes. We demonstrate that the activity of neutralizing monoclonal antibodies
(mAbs)andentry inhibitorsduringcell-celltransmissionvariesdepending ontheir mode of action. While gp41 directed agents
remain active, CD4 binding site (CD4bs) directed inhibitors, including the potent neutralizing mAb VRC01, dramatically lose
potency duringcell-cell transmission.This impliesthat CD4bs mAbs act preferentially through blocking free virustransmission,
while still allowing HIV to spread through cell-cell contacts. Thus providing a plausible explanation for how HIV maintains
infectivity and rapidly escapes potent and broadly active CD4bs directed antibody responses in vivo.
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Introduction
The Human Immunodeficiency Virus (HIV) spreads in vitro
very efficiently, if not preferentially, by cell-cell contacts. Viral
transmission from infected to non-infected cells occurs via
formation of virological synapses – organized contact areas
which concentrate cellular entry receptors and virions [1,2,3,4,5]
- and via transient cell-cell contacts and longer-range intercellular
interactions including nanotubes and filopodia [6,7,8]. Virus
transmission through these points of contiguity has been proven
in vitro to be more efficient and rapid than infection by cell-free
viruses [9,10,11,12,13,14], supporting the notion that cell-cell
transmission may be a relevant if not dominant mode of virus
dissemination in infected individuals. The highly efficient
transmission of HIV between cells may also foster infection of
target cells with multiple virions and so facilitate recombination
and escape adaptations to occur more frequently [15,16,17,18].
So far the relative contribution of cell-cell and cell-free virus
transmission in acquisition of HIV infection and viral dissemi-
nation during human infection remain however undefined. This
gap in knowledge poses a conceptual problem for neutralizing
antibody based HIV vaccine and entry inhibitor design, as it
remains uncertain whether both cell-free and cell-cell spread of
HIV must be blocked with equal efficacy, or whether only the
dominant transmission mode needs to be targeted and if so
which.
Neutralizing antibodies recognize epitopes on the envelope
glycoproteins gp120 and gp41 that are accessible in the oligomeric
form of the HIV envelope protein [19,20]. Neutralization occurs
by blocking virion attachment to host cell receptors or by
inhibiting membrane fusion [19]. To date it remains unclear to
what extent the relatively enclosed environment of the viral
synapse is able to protect the virus from humoral immunity
[21,22]. Previous attempts to determine the capacity of individual
neutralizing antibodies to inhibit cell-cell transmission came to
varying and conflicting conclusions, suggesting it was entirely
inefficient, less efficient than inhibition of cell-free infection, or
indeed equally efficient than inhibition of cell-free infection
[13,22,23,24,25,26]. These discrepancies in reported neutralizing
antibody efficacy in blocking HIV cell-cell transmission underline
the complexity of studying HIV transmission modes and were
suggested to likely reflect incongruities amongst cell types studied
as well as differences in experimental procedures [21]. A number
of studies have shed light on the complexity of HIV transmission
modes and revealed substantial differences amongst experimental
set ups used to study cell-cell transmission [5,13,21,22,27]. Cell-
associated HIV can be transmitted to uninfected target cells by a
variety of modes and may involve both, cells that are productively
infected (cis-infection) and cells that trapped virus but remained
uninfected (trans-infection [28,29,30]. Depending on the cell type
of the counter partners, their relative frequencies and rate of
infection, transmission events can differ on a molecular level and
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structures (T-T cell viral synapse [4], DC-T-cell viral synapse [3],
Macrophage-T-cell [31], polysynapses [7], nanotubes [8], filopo-
dia [32] reviewed in [1]). Considering this broad range of potential
interactions, it is evident that monitoring cell-cell transmission,
precise quantification of the events, and assessment of inhibitor
efficacy has remained most complex. In part conflicting results
obtained on neutralizing antibody efficacy in blocking HIV cell-
cell transmission [13,22,23,24,25,26] may be a consequence of the
variable types of cell-cell interactions engaged in contacts between
cells of different origin as well as differential assay set ups and
readouts.
The primary intent of our current study was to derive a definite
conclusion on the capacity of neutralizing antibodies to block cell-
cell transmission of HIV. Our current knowledge of the
mechanism by which antibodies neutralize HIV is largely based
on data derived in assay formats which assess cell-free virus
infection of a variety of target cells, either in single round or
multiple round infection assays [33,34,35,36,37,38]. While the
former assays only monitor free virus entry, the latter measure a
composite of free virus and cell-cell transmission during consec-
utive rounds of replication.
Several types of experimental approaches have been employed
to dissect cell-free from cell-cell transmission when infected cells
are used as source of virus inoculum. Single virus tracking by
confocal microscopy [39,40], disturbance of cell-cell contacts by
keeping cultures in motion [14] and careful time course analysis of
virus transmission to restrict analysis to a time window when
mostly cell-cell transmission occurs [18,22,26]. The latter
approach has been the most promising to date. Yet these assays
require careful fine tuning of a relatively short infection interval.
Virus transfer due to the short interaction can be relatively low,
require sensitive detection systems and can be error prone [22].
Here we made use of assay systems which allow overcoming
several limitations and explicitly monitoring cell-cell transmission.
The comprehensive in vitro analysis of inhibitor activity during cell-
free and cell-cell virus transmission that we present here provides a
necessary first step towards the definition of the in vivo relevance of
the respective transmission modes and ensuing requirements for
their inhibition by vaccine induced antibody responses and entry
inhibitors.
Results
Quantitative dissection of cell-cell and cell-free
transmission of HIV-1
An inherent difficulty in dissecting neutralizing antibody action
on cell-free and cell-associated virus is related with the respective
assay systems used to evaluate the cell-cell transmission events.
While cell-free infection can easily and most precisely be
quantified (eg by using single-round infecting viruses), genuine
cell-cell transmission is difficult to assess when transmission from
infected to uninfected cells is studied. Replication competent virus
is required in these settings. Although close cell contacts favor
synapse formation and cell-cell transmission [14], entirely
excluding the contribution of free virus transmission has thus far
remained difficult.
To construct a robust high-throughput system allowing direct
comparisons between cell-free and cell-cell transmission we chose
the widely used luciferase reporter cell line TZM-bl as target cells
[34]. PBMC infected with primary, replication competent (rc)
virus isolates served as donor cells in our cell-cell transmission
system as these should most closely resemble in vivo infected cells.
Direct co-culturing of infected PBMC (PBMC
HIV+) with TZM-bl
cells results in rapid and efficient infection of these cells and can be
monitored by induction of the reporter luciferase (Fig. 1A). In
order to adapt the PBMC
HIV+/TZM-bl infection system to
specifically quantify cell-cell transmission we made use of the fact
that many CCR5 (R5) using HIV strains are only capable of
efficiently infecting engineered, CCR5 and CD4 expressing target
cell lines such as TZM-bl in the presence of polycations
[34,41,42]. We found that whilst cell-free infection by the R5
isolate JR-FL was dramatically reduced by the omission of DEAE
Dextran (Diethylaminoethyl Dextran) (Fig. 1B), cell-cell transmis-
sion between JR-FL infected PBMC and the TZM-bl target cells
was polycation independent (Fig. 1A). Free virus released from
infected cells in the cell-cell transmission set up failed to infect in
absence of polycation (Fig. S1A).
In line with previous reports [9,11,12,13,14,22], HIV infection
kinetics in the PBMC
HIV+/TZM-bl transmission assay were
accelerated compared to free virus infection (Fig. S1B). Of note,
regardless of whether cell-free virus adsorption was enforced by
spinoculation [43] or magnetic beads [44], entry of cell-free HIV-
1JR-FL into TZM-bl cells remained severely restricted when no
polycation was added (Fig. 1C), reinforcing the notion that
enhanced virus transmission during cell-cell contact involves
activities that extend beyond a mere increase in membrane
proximity. In order to discriminate cell-cell from cell-free virus
transmission in the PBMC
HIV+/TZM-bl infection assay, polyca-
tion dependent virus isolates were used (Fig. S2). Input of infected
donor cells and cell-free virus input was calibrated so that infection
of both occurs in the linear range of the assay system (Fig. 1A and
1B) and that free virus cannot infect in absence of DEAE-Dextran
(Fig. 1B and S2A). In sum, these assay conditions allowed precise
quantification of cell-cell transmission without interference of free
virus infection in the PBMC
HIV+/TZM-bl infection system.
Mode of virus transmission differentially steers
susceptibility to entry inhibitors
Using defined DEAE-Dextran dependent virus isolates (Fig. S2),
we next employed the PBMC
HIV+/TZM-bl cell-cell transmission
assay to evaluate whether the mode of HIV transfer has an
Author Summary
HIV is known to spread both in a cell-free state and from
cell to cell, however the relative importance of the cell-cell
transmission mode in natural infection has not yet been
resolved. Design of vaccines attempt to inhibit HIV entry
into target cells as do engineered entry inhibitors used as
therapeutics. While these agents are known to block the
entry of cell-free HIV particles into cells, to what extent
cell-cell transmission is vulnerable to such inhibition is
unclear. Here we report that the activity of neutralizing
antibodies and inhibitors during cell-cell transmission
varies depending on their mode of action. A prominent
class of neutralizing antibodies directed to the CD4
binding site on the virus envelope very efficiently blocks
binding of the virus to its primary receptor on target cells,
the CD4 molecule. These types of antibodies are elicited in
natural infection and once isolated from infected individ-
uals have shown to be highly potent. Why HIV still
replicates in the presence of such potent antibodies
remains unclear. Here we show that these CD4 binding site
antibodies are dramatically less potent inhibitors of cell-
cell transmission, and therefore act preferentially by
blocking free virus transmission while allowing HIV to
spread through cell-cell contact.
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PLoS Pathogens | www.plospathogens.org 2 April 2012 | Volume 8 | Issue 4 | e1002634Figure 1. Mode of virus transmission differentially steers susceptibility to entry inhibition. (A) DEAE-Dextran is not required for
effective cell-cell transmission of HIV-1JR-FL to TZM-bl cells. Serial dilutions of JR-FL infected PBMC were incubated with TZM-bl cells in
presence (black circles) or absence (red circles) of 10 mg/ml DEAE-Dextran. Infectivity was measured by enzymatic activity of the luciferase reporter
(relative light units (RLU)). Each infected cell input was probed in triplicate. Error bars represent SD (standard deviation). One of four independent
experiments is shown. (B) Omission of DEAE-Dextran as media supplement abolishes cell-free JR-FL infection of TZM-bl cells. Serial
dilutions of cell-free JR-FL virus were used to infect the luciferase reporter cell line TZM-bl in presence (black squares) or absence (red squares) of
10 mg/ml DEAE-Dextran. Infectivity was measured by induction of the luciferase reporter (relative light units (RLU)). Each virus dilution was probed in
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inhibitors. We compared the inhibitory potency of the gp120-
directed tetrameric CD4-IgG2 molecule (PRO 542) and the gp41-
directed fusion inhibitor T-20 against the isolate JR-FL in cell-free
and cell-cell virus transmission. Strikingly, inhibition of cell-cell
transmission by CD4-IgG2 required an approximately 40-fold
higher 50% inhibitory dose (IC50) than inhibition of the same
virus strain during cell-free infection (Fig. 1D). In contrast, the
gp41 directed fusion inhibitor T-20 was markedly less affected by
the transmission mode requiring only 3-fold higher IC50 doses
during cell-cell transmission. To verify whether the decreased
sensitivity towards CD4-IgG2 during cell-cell transmission was
merely due to more efficient adsorption of the virus to the target
cells or an inherent feature of cell-cell transmission, we assessed the
inhibitory capacity of CD4-IgG2 and T-20 against cell-free virus
adsorbed to target cells by spinoculation or by magnetic beads
(Fig. 1E). Both inhibitors remained equally active regardless
whether adsorption of cell-free virus was increased or not,
indicating that indeed cell-cell transmission associated events
caused the loss of CD4-IgG2 activity rather than simple virus
concentration on the target cell surface.
To restrict our assessment to the first round of cell-cell
transmission events we next probed the efficacy of CD4-IgG2
and T-20 against cell-free JR-FL envelope pseudotyped virus
(pseudovirus particle, pp) and in cell-cell transmission using 293-T
cells transfected with plasmids encoding JR-FL pseudotyped virus
as donor cells (Fig. 1F). Like replication competent virus, the JR-
FL
pp proved more resistant to CD4-IgG2 inhibition during cell-
cell transmission and required 190-fold higher concentrations to
achieve 50% inhibition than cell-free pseudovirus (Fig. 1F).
Gp120 specific entry inhibitors have decreased capacity
to block cell-cell transmission
Our initial observations of the distinct effect of cell-cell
transmission on CD4-IgG2 and T-20 activity raised the question
whether the epitope specificity or neutralization mechanism of a
given inhibitor determines its activity during cell-cell transmission
of HIV. To probe this we investigated a panel of well
characterized neutralizing antibodies and entry inhibitors for their
respective potencies against cell-free and cell-associated virus. We
selected inhibitors based upon their mode of action: cell- directed
(CD4 or coreceptor CCR5 blocking; Fig. 2A), virus directed
(gp120 (Fig. 2B) and gp41 specific (Fig. 2C)). Whenever possible
inhibitors that differ in molecular mass and chemical structure
(peptide, small molecule inhibitor, and antibody) were included for
comparison (Table S1).
Comparison of the inhibitor activity under the two transmis-
sion modes revealed an intriguing pattern (Fig. 2D). While cell-
directed inhibitors (anti-CD4, anti-CCR5) blocked cell-cell and
cell-free transmission of JR-FL with almost identical efficacy
(Fig. 2A and D, ,4-fold loss of activity), HIV-1 envelope directed
inhibitors showed a remarkably dichotomous pattern (Fig. 2B–D).
All CD4 binding site specific agents (mAbs b12, VRC01, 1F7, the
tetrameric CD4-IgG2 molecule and the CD4 mimetic CD4M47
[45]) lost considerable potency when cell-cell transmission
occurred (10 to 100 fold decrease in activity reflected in
according increase in IC50). Of particular note were the results
we obtained for mAb VRC01. While VRC01 is one of the most
potent antibodies in inhibiting cell-free transmission described to
date [46,47], it proved particularly ineffective in inhibiting cell-
cell transmission of JR-FL. Similarly to the CD4bs specific agents,
the carbohydrate specific mAb 2G12 also lost considerable
activity when blocking of cell-cell transmission was required. This
was in sharp contrast to the gp41 specific agents, the MPER-
targeting neutralizing antibodies 2F5 and 4E10 and the fusion
inhibitor T-20 which were all only marginally affected by the
mode of virus transmission (Fig. 2C). Particularly surprising were
the activities of the two MPER specific mAbs, despite the fact
that they are not potent inhibitors of cell-free JR-FL virus
transmission, their ability to block cell-cell transmission remained
in the same range.
The data we obtained thus far supported the notion that virus
directed entry inhibitors fall into two distinct classes with a
differential activity during cell-cell transmission: such that lose
potency (eg CD4bs directed agents) and such which appear
largely unaffected in their activity irrespective of the virus
transmission mode (gp41 directed agents). We next verified the
differential activity of specific CD4bs directed agents (CD4-IgG2
and VRC01) and the gp41 directed agents (2F5, 4E10 and T-20)
in cell-cell and free virus transmission using four genetically
divergent viruses, the Tier-1 virus ADA, the Tier-2 isolates
ZA015, ZA016 and the Tier-3 isolate ZA110 (Fig. 3). The same
pattern of reactivities was also seen for these viruses: CD4bs
directed agents lost substantial potency during cell-cell transmis-
sion, while MPER mAbs and T-20 were only marginally affected
(,4-fold for MPER mAbs).
quadruplicates. Bars represent SD . One of four independent experiments is shown. (C) Cell-cell transmission but not enforced contact
between virus and target cell overcomes entry restriction. The infectivity of cell-free virus without enforced attachment to TZM-bl target cells
(gravity sedimentation), or upon spinoculation, magnetic bead virus adsorption and during cell-cell transmission was assessed in presence (solid
lines) or absence (dotted lines) of 10 mg/ml DEAE-Dextran. Infection was determined by measuring luciferase production after 48 h (recorded as RLU).
Each virus dilution was probed in duplicates. Bars represent SD. One of three independent experiments is shown. (D) Inhibitory profiles of CD4-
IgG2 and T-20 during cell-cell and cell-free transmission. TZM-bl target cells were either cocultivated with JR-FL infected PBMC (red circles, no
DEAE) or cell-free virus (black squares, with 10 mg/ml DEAE) in the presence of increasing doses of CD4-IgG2 (left panel) or T-20 (right panel). Infection
was determined by measuring luciferase production after 48 h and recorded as RLU. Red and black values denote IC50 (nM) of during cell-cell and
cell-free transmission, respectively. Data points represent means of duplicates from three independent inhibition experiments. Bars represent SEM.
Lines depict fitted dose response curves. (E) Decreased CD4-IgG2 sensitivity during cell-cell transmission is due to an inherent feature of
cell-cell transmission. TZM-bl target cells were mixed with replication competent infected JR-FL
rc PBMC in the presence of CD4-IgG2 or T-20 (red
bars) in medium lacking DEAE Dextran. Cell-free JR-FL
rc was either spinoculated (hatched bars), adsorbed by magnetic beads (checkered bars) or
added without enforced adsorption (grey bars) onto TZM-bl target cells in medium containing DEAE Dextran in the presence of the inhibitor. Fold
increases in IC50 of cell-cell compared to cell-free infection are indicated on top of the respective bars. Bars depict means of three independent
experiments in duplicates. Lines denote SD. Inhibition of cell-cell transmission by CD4-IgG2 and T-20 (red bars) was significantly less efficient than
blocking of cell-free virus (grey bars) infection (Student t-test, p,0.0001 in both cases). (F) Single round infection is highly resistant to CD4-
IgG2 inhibition during cell-cell transmission. TZM-bl target cells (no DEAE) were co-cultivated with JR-FL pseudovirus transfected 293-T cells in
the presence of CD4-IgG2 or T-20. Cell-free JR-FL
pp-lucAM was added to the TZM-bl (with 10 mg/ml DEAE) in the presence of both inhibitors. Fold
increases in IC50 of cell-cell compared to cell-free infection are indicated on top of the respective bars. Bars depict means of three independent
experiments performed in duplicates. Lines denote SD. Inhibition of cell-cell transmission by CD4-IgG2 and T-20 (red bars) was significantly less
efficient than blocking of cell-free virus (grey bars) infection (Student t-test, p,0.0001 in both cases).
doi:10.1371/journal.ppat.1002634.g001
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directed inhibitors
While the PBMC
HIV+/TZM-bl assay proved very robust and
provides a means to study cell-cell transmission under tightly
controlled conditions, it has two major limitations. For one, only
R5 viruses which depend on polycation in order to infect the
engineered target cells can be studied. Secondly, while TZM-bl
cells are widely used as target cells in HIV neutralization assays,
they are of epithelial origin and engineered to express CD4 and
CCR5 in abundance [41]. Considering that type and densities of
cellular receptors engaged in forming the virological synapse may
differ to some extent depending on the types of cells engaged, we
thought it prudent to verify our observations in a setting of T-cell
to T-cell transmission.
To this end we employed an alternate assay system making use
of the intracellular HIV restriction factor TRIM5a. While HIV
has adapted to human TRIM5a (huTRIM5a), HIV infection is
potently restricted by rhesus macaque TRIM5a (rhTRIM5a)
which acts post-entry at steps preceding integration [48,49,50].
Notably this restriction appears to limit cell-free virus infections,
but not cell-cell transmission [51]. We made use of this selective
action of rhTRIM5a and generated A3.01-CCR5 T-cells which
co-expressed GFP and either huTRIM5a or rhTRIM5a as
described [51]. While the parental A3.01-CCR5 T-cells are
permissive for HIV and cells transduced with huTRIM5a
remained permissive, rhTRIM5a expression rendered the
A3.01-CCR5 T-cells highly resistant to infection by cell-free virus
(Fig. S3A) but not to infection by HIV via the cell-cell transmission
route (Fig. S3B). Most importantly for our transmission studies
rhTRIM5a restriction of cell-free infection occurs irrespective of
coreceptors usage (Fig. S3A) and hence allows measurement of
cell-associated virus transmission with a wider spectrum of virus
isolates.
To probe the effect of entry inhibitors in T-cell to T-cell
transmission we performed inhibition assays using HIV infected
A3.01-CCR5 cells (A3.01-CCR5
HIV+) as donor cells and
rhTRIM5a expressing A3.01-CCR5 cells as targets (A3.01-
CCR5
rhTRIM5a) (Fig. 4A and B). We observed the same pattern
of virus specific entry inhibition as in the PBMC
HIV+/TZM-bl
assay (Fig. 2). Gp41 directed inhibitors had similar or only slightly
reduced activities in inhibiting the Tier-1 viruses SF162 (R5) and
NL4-3 (X4) and the Tier-2 isolate JR-CSF (R5) during cell-cell
transmission. In contrast CD4bs directed agents lost again
considerable potency during cell-cell transmission. The V3 loop
specific neutralizing antibody 447-52D [52], showed a strain
dependent pattern. While 447-52D inhibition of NL4-3 was
decreased from 90% to 14% during cell-cell transmission, only a
marginal loss of SF162 inhibition occurred. Cell-free NL4-3 and
SF162 is inhibited by 447-52D with similar potency [53],
suggesting that differential V3 loop exposure during the entry
process steers the efficacy of the mAb during cell-cell transmission,
rather than higher potency. In line with this a second V3 loop
antibody 1-79 [54] also blocked cell-free and cell-cell transmission
of SF162 with identical potency (Fig. S4A).
To verify our findings in a setting where transmission was
studied solely on primary T-cells, we generated rhTRIM5a
expressing PBMC and monitored their infection by cell-free virus
and cell-associated virus using HIV infected PBMC (Figure 4C).
The data obtained in the PBMC
HIV+/PBMC
rhTRIM5a assay
confirmed our findings in the PBMC
HIV+/TZM-bl and A3.01-
CCR5
HIV+/A3.01-CCR5
rhTRIM5a assays, and showed decreased
activity of CD4bs antibodies, strain dependent reduction of V3
mAb inhibition and comparable activity of gp41 directed
inhibitors during cell-cell transmission.
Capacity to interfere with HIV attachment to target cells
is not a prerequisite for neutralizing antibodies to block
cell-cell transmission
Our analysis of entry inhibitor activity in cell-cell transmission
thus far had revealed a dichotomous pattern for virus envelope
directed agents. While most gp120 directed agents, and in
particular CD4bs agents, suffered from a considerable loss in
activity during cell-cell transmission, gp41 directed inhibitors
maintained their activity. We hypothesized that the basis for this
dichotomy could be a genuine difference in inhibition modes and
that the capacity to inhibit a specific phase of the entry process
determines efficacy in blocking cell-cell transmission. To explore
this we first evaluated the capacity of neutralizing antibodies to
block attachment of fluorescently labeled HIV to target cells
during spinoculation (Fig. 5A). Within this setup virus binding to a
variety of cell lines and PBMC proved to be predominantly driven
by binding of virions to CD4 (Fig. 5B). In contrast to previous
reports [55], only marginal attachment of HIV to CD4 negative
cells was detected in our assay set up. CD4 independent
attachment of HIV to target cells was previously found
predominantly amongst X4 isolates which were shown to bind
cell surface expressed glycosaminoglycans (GAG) when target cells
were incubated with concentrated virus stocks at 37uC [55,56].
Our current analysis required assessment of attachment in a
setting where binding of virions to cells is both, synchronized and
entry halted before fusion. We achieved this by using spinoculation
and a temperature arrest at 23uC and found that under these
conditions non-CD4 driven attachment is negligible.
In line with the CD4 dependence in the attachment assay,
CD4bs directed inhibitors, b12, VRC01 and CD4-IgG2 potently
inhibited binding of JR-FL (R5) and NL4-3 (X4) to target cells
(Fig. 5C and 5D). Interestingly, the V3 loop specific mAb 447-52D
possesses a partial activity in inhibiting attachment of NL4-3 to
target cells, suggesting that in some virus/antibody pairings co-
receptor engagement may play a role in establishing firm
attachment. In contrast MPER-directed antibodies 2F5 and
4E10 and the fusion inhibitor T-20 were not able to inhibit
attachment. The latter is in accordance with the previously
described limited capacity of MPER mAbs to neutralize virions
before CD4 engagement [38,57,58].
Figure 2. Markedly decreased sensitivity of HIV entry to gp120 directed inhibitors during cell-cell transmission. (A–C) TZM-bl target
cells were either infected with cell-free JR-FL
rc (black squares, with DEAE) or cocultivated with JR-FL
rc infected PBMC (red circles; no DEAE) and
inhibition by cell directed (A), gp120 directed (B) and gp41 directed (C) antibodies and inhibitors studied. Infection was determined by measuring
luciferase production after 48 h (recorded as RLU). Lines depict fitted results derived from three to five independent experiments in which each
sample condition was performed in duplicates. Error bars depict SEM. Dotted lines indicate 50% inhibition levels. (D) Loss of inhibitory activity
during cell-cell transmission. Loss of inhibitory activity during cell-cell transmission compared to cell-free transmission is depicted as fold
difference of IC50 values determined from data depicted in Fig. 2A–C. A star (*) denotes where the respective inhibitor did not reach a 50% inhibition
level at the highest concentration used. The highest concentration probed was used in these cases as minimum estimate to derive the fold
differences in IC50 values.
doi:10.1371/journal.ppat.1002634.g002
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PLoS Pathogens | www.plospathogens.org 6 April 2012 | Volume 8 | Issue 4 | e1002634Figure 3. CD4bs directed inhibitors loose while gp41 directed agents maintain activity during cell-cell transmission across
divergent HIV-1 isolates. (A) TZM-bl target cells were either infected with cell-free, replication competent viruses (black squares, with DEAE) or
cocultivated with infected PBMC (red circles; no DEAE) and inhibition by the indicated antibodies and inhibitors studied. Virus isolates used (ADA,
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maintain potency during cell-cell transmission
Following gp120 binding to CD4, HIV-1 enters its target cell in
a multistep, temporally defined process (reviewed in [59]). In order
to measure the inhibitory capacity of neutralizing antibodies on
virus entry at two different stages of the infection process, we
assessed virus-cell fusion utilizing b-lactamase (BlaM) loaded
virions as described [60,61] (Fig. 6A). Inhibitors were either
added before HIV attachment to target cells and were removed
following spinoculation or alternatively added after HIV attach-
ment to target cells, hence providing a method by which post-CD4
engagement inhibitory activity can be measured. As expected
when inhibitors were added before virion binding to PBMC or
A3.01-CCR5 target cells and were present throughout the
attachment process, all probed compounds potently blocked virus
fusion (Fig. 6B and C). However, addition of inhibitors after
attachment of the virus to the target cells, revealed a dichotomous
pattern. CD4bs reactive agents completely lost their activity while
the MPER-specific antibodies and the gp41-directed fusion
inhibitor T-20 still possessed substantial inhibitory activity. The
capacity of the gp41-directed agents to block infection post CD4
recruitment, is in line with previous reports observing MPER
mAbs and HR1 and HR2 targeting inhibitors which act at a
prefusion stage [57,58,62,63,64,65,66].
This divergent pattern of reactivities of gp120 CD4bs and gp41
directed agents in the fusion assay paralleled their capacity for
inhibition of cell-cell transmission, raising the possibility that
neutralizing activity post-CD4 engagement is required for efficient
blocking of cell-cell transmission.
To resolve pre- and post-attachment activity of inhibitors in
more detail, we infected A3.01-CCR5 cells with envelope
pseudotyped luciferase reporter viruses again performing treat-
ment with neutralizing antibodies before or after attachment of the
virus particles to the cells (Fig. 7A). For all four pseudoviruses
probed (NL4-3, SF162, JR-FL and 6535) the potency of gp120
CD4bs directed reagents (CD4-IgG2, CD4M47 and mAb b12)
was dramatically reduced when added after receptor engagement
(Fig. 7B). Since the peptidic inhibitor CD4M47 experienced the
same difficulties in blocking cell-cell transmission as the CD4bs
antibody and CD4-IgG2 despite its small size, the limited capacity
of mAbs to access the CD4bs during cell-cell transmission is
unlikely to be responsible for their reduced activity during cell-cell
transmission. In contrast to CD4bs agents, the potency of the
gp41-directed inhibitor T-20 and the MPER-specific antibodies
remained essentially unchanged when added after receptor
engagement. The V3 loop mAb 447-52D showed an intermediate
pattern, it lost more than 50% of its activity against NL4-3 and
SF162, but activity against the isolate 6535 was preserved,
indicating again that V3 loop exposure post CD4 binding varies
in a strain dependent manner. Importantly, strain 6535 was
inhibited with identical activity by 447-52D during cell-cell
transmission (Fig. S4B). The same was true for the V3 loop
mAb 1–79 which blocked SF162 potently post attachment (Fig.7C)
and during cell-cell transmission (Fig. S4A).
Anti-CD4 directed agents (CD4-DARPin 57.2, anti-CD4 mAbs
OKT4A [67] and 13B8.2 [68]) showed decreased activity when
added post attachment, while anti-CCR5 inhibitors (AD101,
PRO140, PSC-RANTES) had, in most cases, comparable activity
when present before and after attachment (Fig. 7C). This
observation suggests that under these assay conditions coreceptor
engagement has not been fully established prior to inhibitor
addition. The decreased activity of the anti-CD4 inhibitors in the
post-attachment assay is expected from their mode of action.
These CD4 receptor directed agents nevertheless block free-virus
transmission and cell-cell transmission equally well, while CD4bs
gp120 directed inhibitors do not. This highlights the advantage
cell-directed inhibitors have, as their target is accessible before and
during envelope attachment. In contrast virus-directed inhibitors
only have a narrow window of opportunity to act - after virus
envelope proteins are expressed and transported to the surface of
infected cells.
Discussion
The primary aim of our current study was to dissect the efficacy
of neutralizing antibodies and entry inhibitors in the context of
cell-cell transmission of HIV. It is generally agreed that
neutralizing antibody responses will be a key component of an
effective HIV vaccine [69,70]). However, whether vaccine elicited
neutralizing antibodies will need to block only the infecting
inoculum, or whether protection will also require restriction of
consecutive rounds of infection, and hence inhibition of both cell-
free and cell-cell transmission with equal efficacy is not known.
Likewise, in established infection, should one of the transmission
modes prove to be clearly dominant, this mode may need to be
targeted preferentially by therapeutic vaccines and entry inhibi-
tors.
While it is known that HIV spreads highly efficiently through
various types of cell-cell contacts [9,10,11,12,13,14], so far no
consistent picture of antibody action during this process has
emerged [13,22,23,24,25,26]. Only few neutralizing antibodies
and inhibitors have been probed for their efficacy in cell-cell
transmission, amongst these are antibodies and inhibitors related
to those used in our current study (b12 [71], 447-52D [52], 2F5
[72], 4E10 [73,74]; anti-CD4 mAbs Leu3a and Q4120 [75], and
anti-coreceptor inhibitors AMD3100 [76], TAK779 [77]). Several
studies reported that MPER mAbs [13], CD4bs mAbs [13,24], T-
20 [13], and anti-coreceptor agents [4,13] were significantly less
potent inhibitors of cell-cell transmission than cell-free virus
transmission. Others found cell-cell and cell-free neutralization
activity to be equivalent (MPER mAbs [22,25,26], CD4bs mAbs
[26], V3 mAb 447-52D [4], fusion inhibitors T-20 [22] and C34
[26], anti-CD4 agents [4,22,26,40], and anti-coreceptor agents
[22,39]). However the wide range of assay systems used adds
complexity to the interpretation and comparison of the results.
Several experimental approaches did not allow direct comparison
of cell-cell and cell-free transmission in the same setting
[4,13,25,26,39], other assay systems do not allow precise
quantification of inhibitory activity [4,23,25]. Additionally, all
ZA110, ZA015 and ZA016) are indicated on top of the respective columns, inhibitors on the left of the respective rows. Infection was determined by
measuring luciferase production after 48 h (recorded as RLU). Lines depict fitted results derived from two to three independent experiments in which
each sample condition was probed in duplicates. Error bars depict SEM. Dotted lines indicate IC50 values. (B) Loss of inhibitory activity during
cell-cell transmission. Loss of inhibitory activity during cell-cell transmission compared to cell-free transmission is depicted as fold difference of
IC50 values determined from data depicted in Fig. 3A. A star (*) denotes where the respective inhibitor did not reach a 50% inhibition level at the
highest concentration used. The highest concentration probed was used in these cases as minimum estimate to derive the fold differences in IC50
values.
doi:10.1371/journal.ppat.1002634.g003
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PLoS Pathogens | www.plospathogens.org 8 April 2012 | Volume 8 | Issue 4 | e1002634Figure 4. Efficient inhibition of T-cell to T-cell transmission by gp41 directed inhibitors. (A) Inhibition of T-cell to T-cell
transmission. A3.01-CCR5 infected with JR-CSF or uninfected controls were co-cultured with A3.01-CCR5
rhTRIM5a target cells (GFP positive) in the
presence of the indicated inhibitors or medium alone. Infection of target cells was assessed by intracellular Gag staining by flow cytometry.
Percentages of rhTRIM5a expressing, HIV infected cells are indicated. One representative of two independent experiments is shown. (B)
Comparison of cell-free and cell-cell inhibition in rhTRIM5a restricted A3.01-CCR5 cells. Inhibition of cell-cell (cc, red and orange symbols)
and cell-free (cf, black symbols) transmission of virus isolates JR-CSF, SF162 and NL4-3 by inhibitors (CD4-IgG2, b12 and 447-52D: 50 mg/ml, 2F5, 4E10:
100 mg/ml, T-20: 5 mg/ml, see also Table S2) was studied. To probe cell-cell transmission infected A3.01-CCR5 were cocultured with A3.01-
CCR5
rhTRIM5a target cells. To study free virus transmission cell-free virus preparations were used to infect non-restricted A3.01-CCR5 cells. Infection of
target cells was assessed by intracellular Gag staining by flow cytometry as described in A). Infection achieved in absence of inhibitor was set to 100%
and inhibitor activity expressed in relation to this value. Data depicted are means of two to seven independent experiments. (C) Comparison of
cell-free and cell-cell inhibition in rhTRIM5a restricted PBMC. Inhibition of cell-cell (cc, red and orange symbols) and cell-free (cf, black
symbols) transmission of virus isolates SF162 and NL4-3 by inhibitors (CD4-IgG2, VRC01, b12 and 447-52D: 50 mg/ml, 2F5, 4E10: 100 mg/ml, T-20:
5 mg/ml) was studied. To probe cell-cell transmission infected PBMC were cocultured with PBMC
rhTRIM5a target cells. To study free virus transmission
cell-free virus preparations were used to infect non-restricted PBMC cells. Infection of target cells was assessed by intracellular Gag staining by flow
cytometry as described in A). Infection achieved in absence of inhibitor was set to 100% and inhibitor activity expressed in relation to this value. Data
depicted are means of two independent experiments in duplicates.
doi:10.1371/journal.ppat.1002634.g004
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PLoS Pathogens | www.plospathogens.org 9 April 2012 | Volume 8 | Issue 4 | e1002634Figure 5. Attachment of virus is blocked by preventing gp120-CD4 interaction. (A) Schematic illustration of the experimental set up used
to analyze virus attachment. (B) Attachment of virus is driven by binding to CD4. Attachment of HIV to CD4 negative (HeLa, A2.01) and related
CD4 positive cells (TZM-bl, A3.01-CCR5) as well as stimulated, CD8 depleted PBMC was studied using GFP-labeled virus (JR-FL
ppiGFP). The gray-shaded
areas represent the fluorescent signal obtained by flow cytometric analysis of the respective cell line in the absence of HIV. The black lines indicate
fluorescence intensity of bound JR-FL
ppiGFP. (C) Influence of entry inhibitors on HIV attachment. Activity of 2F5 (100 mg/ml), 4E10 (100 mg/ml)
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are technically challenging and can be error prone [22].
Nevertheless, in agreement with our observations, one study also
reported lower activity of the CD4bs mAb b12 during cell-cell
transmission, albeit this difference was rated as non significant by
the authors [22].
and CD4-IgG2 (50 mg/ml) to block attachment of GFP-labeled virus (JR-FL
ppiGFP) to A3.01-CCR5 cells is shown. Histograms of one representative of
three independently performed experiments are shown. (D) Inhibition of HIV attachment by CD4bs and gp41 directed agents. Attachment
(MFI of GFP signal) achieved in absence of inhibitor was set to 100% and inhibitor activity expressed in relation to this value. Data depicted are means
of three independent experiments, error bars denote SEM. Left panel: Attachment of Vpr-GFP labeled TN8 virus (NL4-3 envelope) to PBMC. Middle
panel: Attachment of GFP-labeled virus (JR-FL
ppiGFP) to A3.01-CCR5. Right panel: Attachment of GFP-labeled virus (NL4-3
ppiGFP) to A3.01-CCR5 cells
(individual inhibitor concentration are listed in Table S2).
doi:10.1371/journal.ppat.1002634.g005
Figure 6. Post attachment activity of entry inhibitors. (A) Schematic illustration of the entry assay using BlaM-Vpr labeled virions. (B) JR-FL
pp-
BlaM entry into PBMC was studied in presence and absence of CD4-IgG2 (50 mg/ml). One of three individual experiments is shown. Fluorescence of
uncleaved CCF2/AM was recorded at 520 nm, b-lactamase cleaved CCF2/AM denoting HIV entry at 447 nm. (C) Inhibition of virus entry. Fusion of
JR-FL
pp-BlaM and NL4-3
rc-BlaM with PBMC or A3.01-CCR5 cells was monitored in presence and absence of the indicated entry inhibitors (Inhibitor
concentration: CD4-IgG2 and b12: 50 mg/ml, 2F5 and 4E10 : 100 mg/ml, T-20 10 mg/ml). Grey and orange bars correspond to pre- and post-
attachment conditions respectively as depicted in (A). Data shown are means of three independent experiments, error bars denote SEM.
doi:10.1371/journal.ppat.1002634.g006
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PLoS Pathogens | www.plospathogens.org 12 April 2012 | Volume 8 | Issue 4 | e1002634Here we report on neutralizing antibody activity during cell-cell
transmission using specifically tailored experimental strategies
which enable unambiguous discrimination between the two
transmission modes. The principle by which free virus infection
can be distinguished from cell-cell transmission in these two
systems is different. In the TZM-bl transmission assay free virus
infection of specific R5 viruses can be restricted by omission of the
polycation DEAE-Dextran in the infection medium (Fig. 1B and
S2). In the second assay system we make use of the capacity of the
restriction factor rhesus TRIM5a which potently interferes with
free virus infection but not cell-cell transmitted virions (Fig. S3)
[51]. While the mode and stage of free virus restriction in the two
assay systems are different, the outcome of our analysis of
neutralizing antibody capacity in both systems was identical.
Gp120 directed inhibitors and neutralizing antibodies, in partic-
ular CD4bs directed agents, showed markedly decreased potency
in blocking cell-cell transmission, whereas the probed gp41
directed inhibitors, the fusion inhibitor T-20 and the MPER
antibodies 2F5 and 4E10, demonstrated identical or only
marginally reduced potency. Of particular note are the cell
directed inhibitors. Both CCR5 and CD4 targeting compounds
were equally active during both transmission modes (Fig. 2A).
Although they target the same step in virus entry, namely gp120
interaction with CD4, we found that anti-CD4 inhibition was not
decreased in cell-cell transmission, while CD4bs mAb activity is
markedly lower (Fig. 2B, 3 and 4BC). This is not unexpected.
During cell-cell transmission, inhibitors targeting the cellular
receptors have a clear advantage, CD4 and CCR5 receptors are
always accessible on target cells and inhibitors can bind
immediately. In contrast, virus directed inhibitors depend on the
initiation of the viral synapse formation, as only then the viral
envelope becomes accessible. As the viral synapse formation is
tightly linked to gp120 binding to CD4 [3,4,13], CD4bs specific
inhibitors are likely to only have a narrow time window for action
as evidenced by their loss of activity during cell-cell transmission.
Only a limited number of entry inhibitors have thus far been
probed for their activity during chronic infection in animal
models, and even fewer have reached clinical investigation in
therapeutic settings. At present only two inhibitors, the CCR5
specific inhibitor Maraviroc and the fusion inhibitor T-20 are in
clinical use. Intriguingly, the currently available data may point
towards a potential link between inhibitor action in established
infection in vivo and activity during cell-cell transmission. The
capacity of Maraviroc and T-20 to restrict cell-free and cell-cell
transmission with equal efficacies, and the comparative failure of
CD4-IgG2 to do the same, parallels their differential clinical
success [78,79,80,81,82,83]. It is tempting to speculate that potent
inhibition of cell-cell transmission is a prerequisite for the
therapeutic success of entry inhibitors during established infection.
This would bode well for the development of cell-directed
inhibitors as all CD4 and CCR5 directed inhibitors we probed
potently blocked cell-cell transmission. Importantly this would also
imply that cell-cell transmission is responsible for a substantial
proportion of viral spread in infected individuals.
Will activity against free virus suffice for both prophylactic
vaccine induced antibody responses and prophylactic interventions
with entry inhibitors? Or is inhibition of cell-cell transmission also
required in these settings? Judging from the success of animal
protection/challenge studies performed with b12 [84,85], a mAb
which we find does not inhibit cell-cell transmission efficiently, one
could speculate that potent activity against cell-cell transmission
may not be necessary for prophylactic vaccines. Yet, a dual
function of antibody based vaccines against both incoming cell-
free virus and early cell-cell transmission could potentially enhance
efficacy. Based on our observations we consider it thus prudent to
incorporate cell-cell transmission studies in current pre-clinical
and clinical vaccine assessment to determine whether or not
activity in blocking cell-cell transmission is a correlate of
protection.
It is very intriguing that amongst the neutralizing antibodies
probed the activity of the MPER mAbs and T-20, were the least
affected by the virus transmission modes. 2F5 and 4E10, in
comparison, displayed only modest potency in free virus
inhibition. Yet this activity was largely maintained during cell-
cell transmission suggesting that the window of opportunity of
action for these mAbs is similar during both entry processes.
Several lines of evidence support this hypothesis. MPER specific
antibodies can bind and neutralize free virions before receptor
engagement [38,86], however this process is slow, requiring
several hours. In contrast these mAbs appear to act preferentially
in a cellular context following HIV envelope engagement by CD4.
Once the envelope trimer has bound cellular receptors and
envelope rearrangements proceed, the MPER domain becomes
more accessible allowing the antibodies to rapidly bind and
neutralize the virus [57,58,86,87,88,89]. In line with this we found
that MPER mAbs were not able to inhibit attachment, but blocked
fusion, both when added during or after attachment (Figs. 5–7).
Thus MPER mAbs and T-20 can block virus that has already
bound to receptors, highlighting that processes required for the
transition from receptor engagement to fusion are slow enough for
these agents to act. Most importantly in the context of our current
study, this suggests that the timing of these processes is identical,
regardless of whether free virus or cell-cell transmitted virus is
concerned. Post-CD4 attachment activity was previously also
reported for other neutralizing antibodies besides MPER mAbs
and gp41 targeting inhibitors including V3 loop mAbs and small
molecule inhibitors targeting CCR5 [64,65,66,90], supporting our
observations.
Inhibitors targeting the cellular receptor have immediate access
to CD4 and the coreceptors both during cell-cell and cell-free
transmission, corresponding to the identical activity we observed
in both settings. In turn this highlights that the binding of gp120 to
CD4 in the cell-cell transmission setting must be the rate limiting
step for CD4bs directed agents. Virus specific antibodies and
Figure 7. Gp41 specific inhibitors have broad post-attachment activity. (A) Schematic illustration of the luciferase reporter assay utilized to
assess post attachment activity of inhibitors. (B) Post-attachment activity of virus directed inhibitors. A3.01-CCR5 cells were infected and
treated with inhibitors before or after virus attachment as indicated in (A). (Inhibitor concentration listed in Table S2). Infection of env-pseudotyped,
luciferase reporter viruses JR-FL
pp-lucAM (diamonds), SF162
pp-lucAM (circle), 6535
pp-lucAM (star), NL4-3
pp-lucAM (triangle) was determined after 48 h of
culture by measuring luciferase production (recorded as RLU). Data depict means of pre attachment (black symbols) and post attachment activity (red
and orange symbols) as % inhibition compared to untreated control. Means of three to six independent experiments are shown. (C) Post-
attachment activity of cell directed inhibitors. A3.01-CCR5 cells were infected and treated with inhibitors before or after virus attachment as
indicated in (A). (Inhibitor concentration listed in Table S2). Infection of env-pseudotyped, luciferase reporter viruses JR-FL
pp-lucAM (diamonds) and
SF162
pp-lucAM (circle)was determined after 48 h of culture by measuring luciferase production (recorded as RLU). Data depict means of pre
attachment (black symbols) and post attachment activity (red and orange symbols) as % inhibition compared to untreated control. Means of two to
four independent experiments are shown.
doi:10.1371/journal.ppat.1002634.g007
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size, can only reach the virus envelope once it becomes exposed on
the cell surface. When infected cells are in close proximity to
potential target cells it is likely critical for neutralizing antibodies to
reach the exposed envelope proteins in time, before they
encounter target cell receptors and cell-cell transmission com-
mences.
Once the trimer becomes accessible, CD4 engagement appears
to be initiated too rapidly for CD4bs specific agents to block with
equal efficacy as in cell-free virus transmission. We found that
activity of other gp120 antibodies during cell-cell transmission
such as 2G12 or V3 loop specific mAbs, which arrest virus
infection post-CD4 engagement, can also be substantially reduced
during cell-cell transmission. Interestingly for V3 loop specific
antibodies we noted a differential activity during cell-cell
transmission depending on the mAb and virus strain investigated
(Figs. 4B, 4C and S4). How quickly a given virus envelope
proceeds from CD4 engagement to coreceptor binding and fusion
will likely be determined by its intrinsic reactivity [91] which may
also influence activity during cell-cell transmission. The more
rapid this process the less effective the respective antibody will
likely be in blocking cell-transmission. In line with this we found
that mAb 447-52D blocks virus strains NL4-3, SF162 and 6535
potently when present during attachment, but only strain 6535 at
comparable levels when added post attachment. SF162 was also
inhibited with identical potency when added during pre- and post
attachment by the V3 loop mAb 1–79. Importantly in all cases we
investigated, high post-attachment activity of V3 loop mAbs was
associated with high efficacy in inhibiting cell-cell transmission
(Figs. 4B, 4C, S4 and 7).
A key finding of our study is the failure of CD4bs specific
antibodies to maintain their potency during cell-cell transmission.
A wealth of data on this antibody category has emerged over
recent years. CD4bs specific antibodies are ubiquitously elicited
during natural infection [46,92,93,94,95], subject to escape [96],
and undergo substantial somatic hypermutation to adapt
[54,94,97], which can lead to the generation of broadly active,
potent neutralizing CD4bs specific antibodies [46,71,94]. There is
recent evidence that the evolution of potent neutralizing antibodies
may follow similar paths across individuals and from different
immunoglobulin heavy genes [94].
HIV escapes antibody responses rapidly [98,99,100,101,102].
Accordingly, even the most potent and broadly active antibodies
characterized in recent years [46,47,94,103,104,105,106] have
nonetheless been isolated from individuals who fail to control
viremia. However due to their breadth and potency these mAbs
may indeed prove to be the responses required for an effective,
prophylactic vaccine. Nevertheless their failure to halt disease
progression needs to be understood. Our observations may resolve
the conundrum of how CD4bs mAbs can be so exorbitantly
powerful in vitro and yet to our current knowledge lack comparable
potency in vivo and fail to suppress viremia to undetectable levels
for prolonged periods. We show here that the blocking activity of
CD4bs antibodies is largely directed towards free virus, thereby
restricting virus spread to the cell-cell route. In the resultant setting
their blocking activity is vastly reduced, thus allowing virus
replication and spread to occur. Simultaneously this partial
inhibition scenario likely fosters escape as sufficient replication
under a partial selection pressure is maintained. In vitro and in silico
studies of drug resistance evolution which factored in cell-cell
transmission recently came to similar conclusions [18]. The
continuous selection of virus escape variants, the high somatic
hypermutation of CD4bs antibodies and the emergence of highly
potent CD4bs directed neutralizing antibodies underline that these
antibodies are continuously imposing a selection pressure on the
virus.
In support of our findings, Poignard and colleagues previously
observed that high serum concentrations of b12 and other
neutralizing monoclonal antibodies, which provide protection
against free virus challenge, lose their impact in an ongoing
established infection in hu-PBL-SCID mice [107]. Of particular
interest, b12 resistant virus rapidly emerged while wildtype,
neutralization sensitive virus was maintained concurrently, a
finding which corresponds to our proposed scenario where HIV
may in part escape neutralization and maintain infection by cell-
cell transmission.
Based on our observations it is tempting to speculate on the in
vivo relevance of cell-free and cell-cell transmission. We hypoth-
esize that the selection pressure provided by CD4bs mAbs should
be stronger on free virus than on cell-cell transmitted virus. The
fact that CD4bs antibodies can nevertheless maintain an
apparently considerable and continuous selection pressure in vivo
would argue in turn that free virus transmission must be an
important component of viral spread in infected individuals. The
importance of free virus transmission may thereby lie either in a
quantitatively higher contribution to viral spread in the infected
individual or a qualitative asset. Should virus spread preferentially
occur through neutralizing antibody vulnerable free virus
transmission, cell-cell transmission would allow the virus to
maintain replication despite antibody pressure and foster rapid
escape. Alternatively, should cell-cell transmission constitute a
higher proportion of transmission events in vivo, we would argue
that free virus transmission must nevertheless be important,
otherwise the selection pressure on free virus transmission could
not be so pronounced. It is likely that in the latter case cell-cell
transmitted viruses still depend on free virus transmission to reach
anatomically distant sites. This may also be crucial for dissemi-
nation of the virus in as target cell availability at the initial sites of
replication will decrease. However, should cell-cell transmission
indeed be the quantitatively dominant transmission mode, it is
feasible that antibody responses which specifically restrict this
transmission mode could emerge. With the panel of antibodies
probed in our current study we saw preferential blocking of free
virus not cell-cell transmission. It will be intriguing to probe larger
antibody panels in future studies and to determine to what extent
the recently defined, potent quaternary and carbohydrate specific
mAbs [103,104] inhibit cell-cell transmission. Common selection
processes probe free virus transmission thus may not have detected
antibodies targeting cell-cell transmission. Defining whether
antibodies that preferentially target the cell-cell transmission exist,
should aid resolution of the relative importance of this transmis-
sion mode and its inhibition.
Regardless of which scenario holds true, we would argue that
cell-cell transmission and the ensuing virus production from
infected cells cannot be scarce otherwise viremia levels would drop
more dramatically during those periods when the autologous
CD4bs specific neutralization response is effective and restricting
free virus transmission. Of note, viral set points in chronic
infection, while comparatively stable, nevertheless fluctuate,
commonly within a 0.5 to 1 log range [108]. It is tempting to
hypothesize that this fluctuation may be in part the result of
alternating periods of effective neutralization of free virus by the
autologous neutralization response, during which only cell-cell
transmission occurs, followed by periods where the virus has
escaped the neutralization response and both transmission modes
are effective.
In sum our analyses provide compelling evidence that
neutralizing antibodies, depending on their mode of action, differ
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According to current knowledge HIV relies on both transmission
modes to maintain infection in vivo. We therefore argue that the
efficacy of entry inhibitors and neutralizing antibodies to block
cell-cell transmission needs to be considered.
Materials and Methods
Ethics statement
PBMC were purified from buffy coats from anonymous blood
donations from healthy individuals obtained by the Zurich Blood
Transfusion Service (http://www.zhbsd.ch/) under a protocol
approved by the local ethics committee.
Reagents
Properties and sources of antibodies and inhibitors used in this
study are listed in Table S1. DARPin 57.2 was produced as
described [109]. T-20 [110] was purchased from Roche
Pharmaceuticals. Maraviroc [111] was purchased from Pfizer.
CD4M47 was synthesized as described [45] and kindly provided
by J. Robinson.
Cells
293-T and HeLa cells were obtained from the American Type
Culture Collection (ATCC). TZM-bl cells [34], A3.01 and A2.01
T-cells [112] were obtained from the NIH AIDS Research and
Reference Reagent Program (NIH ARRRP). All adherent cell
lines were cultivated in DMEM containing 10% heat inactivated
FCS and antibiotics.
A3.01 cells endogenously express CD4 and CXCR4. The sister
cell line A2.01 is CD4 negative. CCR5 expressing A3.01 cells
(A3.01-CCR5) were generated using retroviral transduction as
described ([41], C. Gordon, A. Trkola and J.P Moore unpublished
data). Suspension cells were cultivated in RPMI containing 10%
FCS and antibiotics.
Stimulated peripheral blood mononuclear cells (PBMC) from
healthy blood donors were prepared as described [36] and
cultivated in RPMI containing 10%FCS, 100 units per ml IL-2
and antibiotics.
Virus preparation and concentration
Env encoding plasmids of subtype B Tier 1 isolates NL4-3 (X4)
[113], SF162 (R5) [114] and 6535 (R5) [115] and Tier 2 JR-FL
(R5) [116] were obtained from the NIH ARRRP.
Env–pseudotyped viruses were prepared by co-transfection of
293-T cells with plasmids encoding the respective Env gene and
the luciferase reporter HIV vector pNLluc-AM [117] as described
[36].
Env-pseudotyped particles (pp) generated with this vector are
denoted Env
pp-lucAM (e.g. JR-FL
pp-lucAM).
Where indicated the corresponding pNLgfp-AM pseudotyping
vector (generated by P. Rusert and P. Ocampo) which encodes
GFP instead of luciferase was used. Env- pseudotyped particles
generated with this vector are denoted Env
pp-gfpAM (e.g. JR-FL
pp-
gfpAM).
Replication competent (rc) virus subtype B Tier-1 isolates ADA
(R5), SF162 (R5), NL4-3 (X4), BZ167 (R5X4), Tier-2 isolates JR-
FL (R5), JR-CSF (R5), ZA015, ZA016 and Tier-3 isolate ZA110
(R5) [53] were propagated on CD8-depleted PBMC and titered as
described [118]. In experiments where replication competent and
pseudotyped virus preparations are compared, viruses are denoted
with rc and pp, respectively (e.g. JR-FL
rc, JR-FL
pp).
Replication competent virions were GFP labeled by two
alternate procedures. We used the full length replication
competent NL4-3 derived HIV-GagiGFP vector [13]. Alterna-
tively, virions were labeled by incorporation of chimeric vpr-GFP
as described [119]. To this end 293-T cells were co-transfected
with a plasmid encoding a full length molecular clone of HIV
(TN8 NL [120]) and the plasmid pEGFP-Vpr (gift from B.
Paxton).
Alternatively, to obtain GFP labeled pseudoparticles, an Env
gene deleted pseudotyping vector was generated from the full
length replication competent HIV-GagiGFP vector [13]. Briefly,
envelope from the HIV-GagiGFP construct was replaced by the
corresponding env-deleted luciferase expressing sequence from
pNLluc-AM via XhoI and EcoRI. This vector (HIV-iGFP) was
then used to generate Env-pseudotyped particles by cotransfecting
293-T cells together with the desired envelope encoding plasmid.
Env-pseudotyped particles generated with this vector are denoted
Env
ppiGFP (e.g. JR-FL
ppiGFP)
Replication competent b-lactamase labeled viral particles NL4-
3
rc-BlaM, were generated by co-transfecting the pCMV4-3BlaM-
Vpr plasmid (gift from W. C. Greene), plasmid pAdVAntage
(Promega) and the replication competent proviral vector TN8 as
described [61]. To generate BlaM-vpr labeled JR-FL env
pseudoviruses (JR-FL
pp-BlaM) 293-T cells were co-transfected with
plasmids pCMV4-3BlaM-Vpr, JR-FL env and pNLluc-AM.
All virus preparations were filtered upon harvesting and
infectivity and/or p24 content determined to quantify input as
described [118]. For the virus attachment and b-lactamase entry
assays virus preparations were concentrated by ultracentrifugation
(2 h at 4uC at 28’000 rpm; swing out rotor SW28, 32% sucrose
cushion).
Generation of TRIM5a expressing cells
Bicistronic lentiviral GFP and TRIM5a expression vectors
huTRIM5a or rhTRIM5a [51] were provided by J.L.Riley.
Lentiviral vectors were produced upon co-transfection of 293-T
cells with the TRIM5a encoding vector, the VSV envelope
encoding plasmid pHEF-VSVG [121] obtained through the NIH
ARRRP) and the packaging plasmid pCMV-dR8.91 ([122]; gift
from D. Trono). A3.01-CCR5 cells were transduced by spinocu-
lating (2 h at 1200 g) 100 lentiviral particles per cells in DMEM
containing 10% FCS, antibiotics, and 10 mg/ml DEAE. PBMC
were transduced one day after isolation and stimulation by
spinoculation (2 h 1200 g) with 800 lentiviral particles in RPMI
containing 10% FCS, antibiotics and 8 ug/ml Polybrene. PBMC
Transduced PBMC were cultured on 48 wells coated with OKT3
and 2 mg/ml CD28 and TRIM5a positive cells were retrieved by
FACS sorting on day 4 after transduction. Expression of
huTRIM5a or rhTRIM5a was monitored by detection of
bicistronic expressed GFP by FACS.
Assessment of free virus and cell-cell transmission in the
PBMC
HIV+/TZM-bl infection system
We developed an assay system based on infection of TZM-bl
cells, which allows easy and quantitative discrimination between
cell-free and cell-cell transmission. This is possible as many R5
viruses depend on polycationic supplements in the cell culture
medium in order to infect TZM-bl cells as cell-free virions but not
during cell-cell transmission (Fig. 1).
For cell-free virus infection, the neutralization activity of mAbs
and inhibitors was evaluated on TZM-bl cells essentially as
described using replication competent virus as inoculum [36].
Cell-free, replication competent virus input was chosen to yield
virus infectivity corresponding to 5’000–10’000 relative light units
(RLU) per 96 well in absence of inhibitors. Cell-free virus
infections were carried out in culture medium containing 10 mg/
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Biosciences, Fairfield, Connecticut, USA) if not otherwise
indicated.
To assess cell-cell transmission and inhibition thereof, stimulat-
ed CD8-depleted peripheral blood mononuclear cells (PBMC)
from healthy blood donors were infected with replication
competent virus stocks at a MOI 0.01. Cell-cell transmission in
the PBMC
HIV+/TZM-bl infection system had the same linear
dynamic range as cell-free transmission (Fig. 1A and B). At the
highest virus or infected cell input a reduction in luciferase
reporter signal is observed due to increased cell death and the
resultant loss of infected TZM-bl cells. Input of infected cells was
chosen as such that ensuing infection of TZM-bl cells was in the
same range as in the free virus infections (virus infectivity
corresponding to 5’000–10’000 relative light units (RLU) per well
in absence of inhibitors). To ensure that cell-cell transmission is
always probed in the linear range of the assay, a titration of donor
cell input, as depicted in Fig. 1A, was included in each individual
experiment. Cell-cell virus infections were performed in culture
medium containing no DEAE if not otherwise indicated. On day 4
post infection, infected PBMC were washed twice to remove free
virions. Cells were then pre-incubated with virus directed
inhibitors for 1 h before co-culturing with TZM-bl target cells
(1610
4 per well). To assess activity of target cell directed agents,
TZM-bl cells were pre-incubated with inhibitors before co-
culturing with infected PBMC. 48 hours after infection cells were
lysed and luciferase reporter gene production measured upon
addition of firefly luciferase substrate (Promega, Madison Wis-
consin, USA). Inhibitor and antibody concentrations causing 50%
reduction in viral infectivity (50% inhibitory concentration, IC50)
were calculated by fitting pooled data from three to four
independent experiments to sigmoid dose response curves
(variable slope) using GraphPad Prism. If 50% inhibition was
not achieved at the highest drug concentration a greater-than
value was recorded.
Only R5 viruses which we determined to depend upon DEAE-
Dextran to efficiently infect TZM-bl cells as free virus inoculum
were used in the PBMC
HIV+/TZM-bl assay (Fig. S2). For these
isolates no infection was detectable over a wide range of virus
input in the absence of DEAE-Dextran. Although this dependence
can be overcome at very high virus concentrations, infectivity
remained 1–2 orders of magnitude lower. Levels of virus and
infected cell input that mediate efficient cell-cell transmission but
restrict free virus infectivity were then employed in the assays. R5
and X4 using virus strains which efficiently infect TZM-bl cells in
the absence of cationic compounds cannot be used in this assay.
While DEAE-Dextran also improves infectivity of these viruses
(Fig. S2), residual infectivity in the absence of the polycation is too
high and impedes precise discrimination of cell-free and cell-cell
infection in the DEAE dependent PBMC
HIV+/TZM-bl infection
system.
Assessment of free virus and cell-cell transmission using
envelope pseudotyped virus particles
We utilized the DEAE dependent TZM-bl infection assay
system also to assess single-round virus infection during cell-cell
transmission using envelope pseudotyped viruses. The pseudotype
backbone used in these experiments (pNLgfp-AM) does not
encode for luciferase, which allowed discrimination between donor
and target cell infection, as only in the TZM-bl target cells
luciferase production will be induced upon infection. Free virus
infection in presence of DEAE was performed as described with
minor modifications [36]. Cell-free virus input was chosen to yield
virus infectivity corresponding to 5’000–10’000 relative light units
(RLU) per 96 well in absence of inhibitors. Virus and inhibitors
were preincubated for 1 h at 37uC in 96 well plates, then TZM-bl
(10
4 per well) were added. To assess the neutralization activity of
mAbs and inhibitors during cell-cell transmission of pseudovirus,
293-T cells (10
4 per well) were seeded in 96-well plates, and 24 h
later transfected with 24 mg of the pseudovirus backbone pNLgfp-
AM and 8 mg of the JR-FL env per plate (0.33 mg per well) - using
polyetheylenimine (PEI, linear 25 kDa, Polysciences) as transfec-
tion agent. Twenty-four hours post transfection virus producing
293-T cells were washed twice with DMEM (10% FCS, P/S) and
pre-incubated with virus directed inhibitors (1 h at 37uC). Then
TZM-bl cells (10
4 per well) were added. No DEAE Dextran was
present in the cell-cell transmission setting. After 48 hours of co-
culture, infection of the TZM-bl cells was monitored by
quantifying the production of the reporter luciferase and the
50% inhibitory concentration (IC50) of the respective drugs was
assessed.
Assessment of free virus and cell-cell transmission using
rhTRIM5a restricted A3.01-CCR5 cells
The neutralization activity of mAbs and inhibitors was
additionally evaluated on cells expressing rhesus (rh) TRIM5a as
they have been shown to restrict preferentially free virus
transmission (Figure S3B and [51]). A3.01-CCR5 were transduced
with human or rhTRIM5a or mock treated and used as target
cells in T-T cell transmission experiments and were co-cultivated
with infected A3.01-CCR5
HIV+. To study free virus infection the
same set of target cells were infected with cell-free replication
competent virus. TRIM5a expression was monitored by the
expression of bi-cistronic expressed GFP. HIV infection of cells
was detected by intracellular p24 staining by FACS using the BD
Cytofix/Cytoperm Fixation and Permeabilization Kit (BD Biosci-
ences) and mAb KC57-RD1 (anti-HIV-1 p24-Gag, Beckman
Coulter), following the manufacturers’ instructions. To assess the
influence of rhTRIM5a on cell-cell transmission, A3.01-CCR5
hu-
TRIM5a, A3.01-CCR5
rhTRIM5a or mock treated A3.01-CCR5 cells
and either co-cultured with infected donor cells (A3.01-
CCR5
HIV+) or cell-free virus 6 days post transduction. The same
virus stocks were used for free virus infections and to infect donor
cells. Infection was monitored after 2–7 days of culture by
measuring Gag protein expression in the target cell population. To
monitor influence of the transmission mode on entry inhibition
cell-cell transmission was assessed by determining efficacy of
inhibition using A3.01-CCR5
rhTRIM5a and infected donor cells
(A3.01-CCR5
HIV+). This was compared to inhibition of free virus
infection of mock treated A3.01-CCR5 cells. Virus input for both
transmission modes was adjusted to yield a comparable output of
approximately 10% Gag positive A3.01-CCR5 cells in absence of
inhibitors. Inhibitor concentrations which yield maximum inhibi-
tion of cell-free virus infection were determined for all compound/
virus pairings and probed at these doses in the cell-cell
transmission setting. Virus directed inhibitors were preincubated
with cell-free replication competent virus or infected A3.01-CCR5
cells (50’000 per 96 well) for 1 h at 37uC. A3.01-CCR5
rhTRIM5a
target cells were added (50’000 per well) and infection allowed to
spread for 2–7 days depending on the growth kinetics of the
respective isolates. Infectivity was assessed by intracellular p24
staining. % inhibition=1002100/[% infected cells in uninhibited
sample] * [% infected cells in sample x]. As control, infection with
cell-free and cell-associated virus was performed using transwell
chambers (12-well 0.4 mm polyester-membrane dishes (Corning
Life Sciences, Corning, NY) and virus inocula (cell-free or cell-
associated) added to the transwell insert. Uninfected human or
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cells in the bottom chamber.
Assessment of free virus and cell-cell transmission using
rhTRIM5a restricted PBMC
The PBMC
HIV+/PBMC
rhTRIM5a transmission assays were
performed essentially as described for A3.01-CCR5 cells. To
assess cell-cell transmission using rhTRIM5a, stimulated, CD8
depleted PBMC were transduced with rhTRIM5a one day after
isolation, sorted 4 days post-transduction and co-cultivated with
infected PBMC one day after sorting. In parallel cells were mock
treated and cell-free inhibition was monitored utilizing the same
virus stocks. Infection was monitored after 3 days of culture by
measuring Gag protein expression in the target cell population.
Virus attachment assay
Vpr-GFP or Gag-iGFP labeled virion attachment to target cells
was studied in presence or absence of entry inhibitors. GFP labeled
viruses were preincubated with virus-directed antibodies or
inhibitors for 1 h at 37uC, then added to wells of a 96-well
round-bottom plates containing target cells (PBMC (100’000 cells/
well); A3.01-CCR5, A2.01, HeLa, and TZM-bl: (50’000 cells/
well)) in a total volume of 100 ml. Attachment of virus to target
cells was synchronized by spinoculation (2 h at 1200 g) at 23uC
[43]. This low temperature allows efficient attachment of virions to
target cells and receptor engagement but impedes virus-cell fusion
[123]. Following spinoculation, unbound virus was removed by
washing cells twice in FACS buffer (PBS, 2% FBS, 0.1% azide).
Cells were then fixed in 1.5% paraformaldehyde (PFA) and GFP
positive cells indicative of virus attachment quantified by flow
cytometry on a CyAn ADP instrument (Beckman Coulter). Data
analysis was performed with FlowJo software (Treestar). The
endogenous green fluorescence of mock treated cells (no virus) was
determined and the mean fluorescence intensity (MFI) of virus
treated samples corrected for this value. 100% attachment (0%
inhibition, medium control) was determined in cells treated with
virus in absence of inhibitors. The inhibition achieved by the
various inhibitors and neutralizing antibodies was expressed
relative to this value. % inhibition of attachment=1002100/
[MFI medium control] * [MFI inhibitor x].
Virus fusion assay
We employed a virion-based fusion assay, which detects the
enzymatic activity of virion co-packaged b-lactamase post fusion,
to assess virus entry essentially as described previously [60,61].
Virus entry is thereby measured as the extent of cleavage of a
cytosolic, fluorogenic substrate by virion co-packaged b-lactamase
(BlaM). The latter is achieved by incorporation of chimeric BlaM-
vpr into viral particles which is delivered to the target cells cytosol
upon successful entry [61]. To test the pre-attachment inhibitory
potency of mAbs and inhibitors, BlaM-Vpr containing viruses
were preincubated with nAbs or inhibitors for 1 h at 37uC. Target
cells (PBMC/100’000 cells/well or A3.01-CCR5/50’000 cells/
well) were added and virus attachment initiated by spinoculation
(2 h, 1’200 g, 23uC). Cells were then immediately washed with
CO2-independent medium (Gibco) to remove unbound virus and
inhibitors. In parallel, to test post attachment activity of entry
inhibitors, the inhibitors or nAbs were added after spinoculation
(after excess unbound virus had been washed off) and were
incubated with the virion bearing cells for 1 h at 23uC. To initiate
virus–cell fusion, samples from both the pre and post attachment
conditions, were incubated for 3 h at 37uC. The cells were then
washed once in medium and loaded with the fluorogenic b-
lactamase substrate CCF2/AM (Invitrogen) and incubated for 1 h
at room temperature following the manufacturer’s instructions.
Cells were then washed twice in developing medium (CO2-
independent medium (Gibco), 2.5 mM probenecid (Sigma), 10%
FBS) and incubated overnight at room temperature to allow the b-
lactamase to cleave CCF2/AM. Following a wash step with PBS,
cells were stained with anti-CD4-APC (Caltag), washed again and
fixed in 3% paraformaldehyde. CD4 positive cells were accounted
for by flow cytometry and cell populations containing uncleaved
CCF2/AM (520 nm, no virus fusion) and cleaved CCF2/AM
(447 nm; virus fusion) determined. Inhibition of fusion was
determined by reduction in cell numbers positive for cleaved
CCF2/AM (447 nm, 450/50 filter) fluorescence and calculated as
% inhibition=1002100/[% infected cells in medium control] *
[% infected cells in inhibitor6treated sample].
Virus entry assay based of luciferase reporter gene assay
To analyze post-attachment activity of mAbs and inhibitors, we
studied infection of A3.01-CCR5 cells by Env-pseudotyped
luciferase reporter viruses. To test pre-attachment activity,
inhibitors and mAbs were pre-incubated for 1 h at 37uC, and
then spinoculated onto A3.01-CCR5 cells as described above.
Unbound virus and inhibitors were washed off immediately after
spinoculation. To test post-attachment activity, virus was first
spinoculated onto A3.01-CCR5 cells, residual virus washed off and
then inhibitors incubated with the virus bearing cells for 1 h at
23uC. Both pre- and post-attachment cultures were then cultivated
for 48 h at 37uC before infection was monitored by determining
luciferase production as described above.
Supporting Information
Figure S1 Dependence of R5 viruses on DEAE-Dextran
during cell-free transmission. (A) Free virus released from
infected donor cells during cell-cell transmission has no impact on
assessment of cell-cell transmission. JR-FL infected PBMC were
co-cultured with HeLa cells (CD4 and CCR5 negative) to mimic
co-culture condition in the PBMC
HIV+/TZM-bl infection system
without allowing cell-cell transmission to occur. Supernatant was
harvested at the indicated time points, transferred onto TZM-bl
cells and assessed for infectivity in absence of DEAE-Dextran.
During the 48 h co-culture period only minute amounts of virus
are released from the infected PBMC which fail to infect in the
absence of DEAE-Dextran. Thus, at the chosen infected cell input,
virus transmission in the PBMC
HIV+/TZM-bl infection system in
absence of DEAE-Dextran occurred almost exclusively through
cell-cell transmission. Data are derived from one of two
independent experiments. Means and SEM of triplicate samples
are shown. (B) Cell-cell transmission is more rapid than cell-free
transmission. Cell-cell transmission of JR-FL from infected PBMC
to TZM-bl in absence of DEAE Dextran (left panel) and cell-free
JR-FL infection of TZM-bl in presence of 10 mg/ml DEAE-
Dextran (right panel) was monitored at the indicated time points
by determining luciferase reporter production (RLU). Data points
are means of triplicate measurements. Bars represent SEM.
(TIF)
Figure S2 R5 viruses differ in their DEAE-Dextran
dependence during cell-free transmission. (A) DEAE-
Dextran dependent cell-free infection of TZM-bl cells by
R5 viruses TZM-bl cells were infected with serial dilutions of
cell-free R5 virus isolates (ADA, ZA110, ZA015 and ZA016) in
presence (black squares) or absence (red squares) of 10 mg/ml
DEAE-Dextran. Infection was determined by measuring luciferase
production after 48 h (recorded as RLU). Each virus dilution was
Inhibition of HIV Cell-Cell Transmission
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independent experiments is shown. (B) Absence of DEAE-
Dextran as media supplement has no effect on cell-cell
transmission of HIV-1 to TZM-bl cells. Serial dilutions of
PBMC infected with different R5 isolates (ADA, ZA110, ZA015
and ZA016) were incubated with TZM-bl cells in presence (black
circles) or absence (red circles) of DEAE-Dextran. Infection was
determined by measuring luciferase production after 48 h
(recorded as RLU). Each infected cell input was probed in
triplicate. Error bars represent SEM. One of two independent
experiments is shown. (C) DEAE-Dextran independent cell-
free infection of TZM-bl cells by certain R5 and X4 using
viruses. TZM-bl cells were infected with serial dilutions of cell-
free R5 virus isolates JR-CSF and SF162, the R5X4 virus BZ167
and the X4 strain NL4-3 in presence (black squares) or absence
(red squares) of DEAE-Dextran. Infection was determined by
measuring luciferase production after 48 h (recorded as RLU).
Each virus dilution was probed in quadruplicates. Bars represent
SEM. One of two independent experiments is shown.
(TIF)
Figure S3 Rhesus TRIM5a restriction allows precise
dissection of cell-free and cell-cell transmission of HIV-
1. (A) Rhesus TRIM5a transduced cells are highly
resistant to cell-free single round and multiple round
infection. Infection of rhesusTRIM5a or mock transduced
A3.01-CCR5 cells with the indicated env-pseudotyped, luciferase
reporter viruses (left panel) or replication competent SF162 isolate
(right panel). Infection of the reporter virus was determined by
measuring luciferase production after 48 h (recorded as RLU/ml).
Infection of SF162 was monitored by determining p24 antigen
production. Both cell-free infection with single round, env
pseudotyped virus and replication competent virus isolates proved
to be almost completely restricted in rhTRIM5a transduced
A3.01-CCR5 cells. One of two independent experiments for each
virus isolate is shown. Error bars represent SEM. (B) Cell-cell
transmission overcomes rhTRIM5a mediated restric-
tion of HIV-1. Uninfected or SF162-infected A3.01-CCR5 cells
(donors) were co-cultivated with the indicated A3.01-CCR5 target
cells (mock treated (no gfp), rhTRIM5a (gfp positive), huTRIM5a
(gfp positive)) either in direct coculture (left panel or separated by
transwells (right panel). Infection was assessed by intracellular
HIV-1 Gag staining after 6 days of coculture. Data show one
representative out of three independent experiments. (C) Cell-
cell transmission but not enforced contact between virus
and target cell overcomes rhTRIM5a mediated entry
restriction. Comparison of the infectivity of cell-free SF162
infection of i) spinoculated, ii) magnetic bead bound virus and iii)
virus added without enforced adsorption with cell-cell transmission
(direct cocultivation and transwell). Infection of mock treated,
rhTRIM5a and huTRIM5a A3.01-CCR5 target cells was
investigated. One representative out of three independent
experiments is depicted. To allow comparison, data are normal-
ized to infection levels obtained by spinoculating cell-free SF162
onto mock transduced cells.
(TIF)
Figure S4 Efficient inhibition of Cell-Cell transmission
by V3 directed antibodies. (A) V3 directed antibody 1–79
efficiently inhibits cell-cell transmission of replication
competent SF162. Activity of V3 loop mAb 1–79 and CD4bs
directed mAb b12 to inhibit cell-cell transmission was studied by
co-cultivating rhTRIM5a transduced TZM-bl with SF162
rc
infected PBMC (red circles; no DEAE in infection media).
Inhibition of free virus transmission of SF162
rc was monitored in
parallel on TZM-bl target cells in absence of rhTRIM5a (black
squares; 10 mg/ml DEAE in infection media). Infection was
determined by measuring luciferase production after 48 h
(recorded as RLU). Lines depict fitted results derived from three
independent experiments in which each sample condition was
performed in duplicates. Error bars depict SEM. (B) Single
round infection by 6535 is sensitive to 447-52D inhibition
during cell-cell transmission. Activity of V3 loop mAb 447-
52D and CD4bs directed b12 to inhibit cell-cell transmission was
studied by co-cultivating rhTRIM5a transduced TZM-bl with
6535 pseudovirus transfected 293-T cells (red circles; no DEAE in
infection media). Inhibition of free virus transmission of cell-free
6535
pp-lucAM was monitored in parallel on TZM-bl target cells in
absence of rhTRIM5a (black squares; 10 mg/ml DEAE in
infection media). Infection was determined by measuring luciferase
production after 48 h (recorded as RLU). Lines depict fitted results
derived from three independent experiments in which each sample
condition was performed in duplicates. Error bars depict SEM.
(TIF)
Table S1 Origin and specificity of mAbs and inhibitors.
This table lists the origin and specificity of all monoclonal
antibodies and inhibitors used in the current study.
(PDF)
Table S2 Antibody and inhibitor concentrations. This
table lists the individual antibody and inhibitor concentrations
used in experiments depicted in Figures 4 to 7.
(PDF)
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